Skip to main content
padlock icon - secure page this page is secure

Dopamine Transporter Ligands: Recent Developments and Therapeutic Potential

Buy Article:

$68.00 + tax (Refund Policy)

The dopamine transporter (DAT) is a target for the development of pharmacotherapies for a number of central disorders including Parkinson's disease, Alzheimer's disease, schizophrenia, Tourette's syndrome, Lesch-Nyhan disease, attention deficit hyperactivity disorder (ADHD), obesity, depression, and stimulant abuse as well as normal aging. Considerable effort continues to be devoted to the development of new ligands for the DAT. In this review, we present some of the more interesting ligands developed during the last few years from the 3-phenytropane, 1,4-dialkylpiperazine, phenylpiperidine, and benztropine classes of DAT uptake inhibitors as well as a few less studied miscellaneous DAT uptake inhibitors. Studies related to the therapeutic potential of some of the more studied compounds are presented. A few of the compounds have been studied as pharmacotherapies for Parkinson's disease, ADHD, and obesity. However, most of the drug discovery studies have been directed toward pharmacotherapies for stimulant abuse (mainly cocaine). A number of the compounds showed decreased cocaine maintained responding in rhesus monkeys trained to self-administer cocaine. One compound, GBR 12,909, was evaluated in a Phase 1 clinical trial.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: 1,4-dialkylpiperazine; 3-phenyltropane; Dopamine transporter; benztropine; phenylpiperidine

Document Type: Research Article

Affiliations: Organic and Medicinal Chemistry, Research Triangle Institute, P.O. Box 12194 / 3040 Cornwallis Road, Research Triangle Park, NC 27709, USA.

Publication date: September 1, 2006

More about this publication?
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more